Drug Information Center (DIC) - Guidelines

A Drug Information Center (DIC) is a specialized facility that provides accurate, unbiased, and timely information about drugs and medications to healthcare professionals, patients, and the general public. The primary aim of a DIC is to promote the rational use of medicines by supporting evidence-based decision-making in clinical practice.

DICs serve as a reliable source for drug-related inquiries, including information about drug dosage, interactions, adverse effects, therapeutic uses, and recent advances in pharmacotherapy. They play a critical role in improving patient safety, enhancing the quality of healthcare, and supporting pharmacovigilance activities.

Objectives of the DIC

  • To provide accurate, unbiased, and evidence-based drug information to healthcare professionals, students, and patients.
  • To promote rational drug use through evaluation of prescriptions and therapeutic interventions.
  • To monitor and improve drug safety, including adverse drug reactions (ADRs) and medication errors.
  • To act as a resource for clinical research, education, and professional development.

Drug Monograph

A drug monograph is a comprehensive document providing detailed information on a particular drug, including:

  • Chemical name & structure
  • Pharmacology & mechanism of action
  • Indications & contraindications
  • Dosage & administration
  • Adverse effects & toxicity
  • Drug interactions
  • Special precautions

Example: Monograph for Metformin:

  • Indication: Type 2 Diabetes Mellitus
  • Contraindication: Renal impairment (eGFR <30 mL/min/1.73 m²)
  • Adverse effects: GI upset, lactic acidosis (rare)

Rx Express Intro

RxExpress is a newsletter published by the Drug Information Center to provide timely updates on drugs, therapies, regulatory changes, safety alerts, and recent research findings. It serves as a knowledge-sharing platform for students, healthcare professionals, and faculty.

Objectives:

  1. Keep healthcare professionals informed about new drug approvals, recalls, and safety alerts.
  2. Promote awareness of latest clinical guidelines and treatment protocols.
  3. Disseminate research highlights, case studies, and innovations in pharmacotherapy.
  4. Support rational prescribing and evidence-based practice.

Content Included in RxExpress:

  • New Drug Approvals: FDA/CDSCO-approved medications, biosimilar, generics
  • Example: Announcement of a new oral anticoagulant for atrial fibrillation.
  • Safety Alerts & Recalls: Adverse drug reactions, black-box warnings, product recalls
  • Example: Recall of a batch of metformin due to impurity detection.
  • Clinical Research Updates: Key findings from recent studies or clinical trials
  • Example: Evidence supporting reduced dose of statins in elderly patients to minimize myopathy.
  • Regulatory News: Changes in drug schedules, prescription regulations, or licensing
  • Example: New government guidelines for antibiotic stewardship in hospitals.
  • Educational Articles: Case studies, drug interaction highlights, or dosing strategies
  • Example: Case report on drug-induced liver injury due to herbal supplements.

Will include “New Approvals,” “Safety Alerts,” “Research Highlights,” “Regulatory News”

Example Entry in RxExpress.

Title: “FDA Approves Oral Antiviral for COVID-19”

Summary: Newly approved drug X reduces hospitalization risk by 50% in mild to moderate COVID-19 patients. Recommended dose: 300 mg twice daily for 5 days. Check for interactions with anticoagulants.

References & Sources

DIC queries should be answered using reliable and updated sources:

  • Primary literature: PubMed, clinical trials
  • Secondary literature: Review articles, guidelines
  • Tertiary sources: Lexicomp, Micromedex, Martindale, British National Formulary (BNF)
  • Official resources: WHO, FDA, CDSCO

Types of Cases Handled

The DIC handles a wide variety of queries, including:

  • Dosage Check
  • Example: Calculating pediatric dose of amoxicillin for a 20 kg child.
  • Drug Interactions
  • Example: Checking interaction between fluconazole and warfarin.
  • Contraindications
  • Example: Advising against NSAIDs in a patient with peptic ulcer disease.
  • Drug Safety Profile
  • Example: Evaluating long-term safety of statins in elderly patients.
  • Prescription Audit
  • Example: Reviewing prescriptions in the hospital for polypharmacy risks.
  • Medication Errors
  • Example: Identifying wrong dose prescriptions and suggesting correction.
  • Bioavailability or Alternative Drug
  • Example: Suggesting IV paracetamol instead of oral for patients unable to swallow.
  • Dose Calculation
  • Example: Calculating creatinine clearance to adjust digoxin dose.

Process for Responding to Queries

Query Reception: Queries received via email, phone, or in-person.

Data Collection: Collect patient-specific details (age, weight, comorbidities, lab results).

Literature Search: Review primary, secondary, and tertiary sources for accurate information.

Analysis & Recommendation: Evaluate risk-benefit and provide evidence-based advice.

Documentation: Record the query, references used, and advice given.

Feedback: Follow-up to assess outcome or clarify further doubts.

Example: A doctor requests information on anticoagulant dosing in renal impairment. The DIC reviews guidelines, calculates dose adjustments, and documents the advice.

Collaboration and Networking

The DIC collaborates with:

  • Hospital pharmacists and clinicians for patient care
  • Other DICs and academic institutions for knowledge exchange
  • Regulatory authorities (CDSCO, FDA, WHO) for drug safety updates
  • Professional bodies (IPA, AICTE) for continuing education programs.

Example: Collaboration with Ruby Hall Clinic to provide workshops on adverse drug reaction reporting.

References

  • American Society of Health-System Pharmacists. ASHP Guidelines on Pharmacy-Based Drug Information Services. 2018.
  • WHO. Pharmacovigilance Guidelines for Setting Up a Drug Information Center. 2020.
  • Lexicomp Online, Wolters Kluwer.
  • Martindale: The Complete Drug Reference, 41st Edition.
  • British National Formulary (BNF) 2025.
  • . FDA Drug Safety Communications: www.fda.gov/drugs/drug-safety-and-availability
  • CDSCO Updates: www.cdsco.gov.in